The application provides a polypeptide comprising the sequence SLMTNLAAL (SEQ ID NO: 8), Ser 13 to Leu 21 of amino acid sequence shown in FIG. 1 or SEQ ID No 1, and having HLA-A2 haplotype binding activity, or a polynucleotide encoding said polypeptide. Vaccines containing the polypeptide or polynucleotides encoding the polypeptide are also provided.

Methods for attenuating or treating, or reducing the mortality of sepsis or septic shock using an ectonucleotidase such as CD39 or CD73 are provided.

The invention provides a combination of a source of a CD39 and of a source of a CD73.

Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.

This invention relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5 nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

A method of making nicotinamide riboside, nicotinamide riboside derivatives, or mixtures thereof is disclosed. The method involves contacting at least the following materials to form a solution: i) -D-ribose-1-phosphate, -D-ribose-1-phosphate derivatives, or mixtures thereof; ii) nicotinamide, nicotinamide derivatives, or mixtures thereof; iii) one or more pentosyl transferases (E.C. 2.4.2); iv) and one or more solvents. The resulting solution comprises nicotinamide riboside, nicotinamide riboside derivatives, or mixtures thereof and one or more inorganic orthophosphate anions. The inorganic orthophosphate anions are removed from the solution, leaving a solution of nicotinamide riboside, nicotinamide riboside derivatives, or mixtures thereof.

The application provides a polypeptide comprising the sequence SLMTNLAAL, Ser 13 to Leu 21 of amino acid sequence shown in FIG. 1 or SEQ ID No 1, and having HLA-A2 haplotype binding activity, or a polynucleotide encoding said polypeptide. Vaccines containing the polypeptide or polynucleotides encoding the polypeptide are also provided.

A method for producing a cyclic peptide, comprising using a penicillin-binding protein-type thioesterase (PBP-type TE) or a tyrocidine synthase TycC thioesterase domain (TycC-TE) as a catalyst, wherein a diol as a leaving group is attached to a carboxyl group of a C-terminal residue of a substrate; and a method for producing a peptide serving as the substrate using a solid phase carrying a diol.

This application provides a glycosyl-modified fusion protein, a nucleic acid molecule, an expression vector, a host cell and use thereof. A first aspect of this application provides a glycosyl-modified fusion protein including a murine Fc variant and a prostate cancer antigen, where the murine Fc variant is obtained by subjecting a murine Fc fragment to amino acid mutation and non-mammalian glycosylation-modification; the murine Fc variant includes at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330 and glutamic acid at position 332; the non-mammalian glycosylation-modification excludes sialic acid-modification; the position numbering is performed according to the EU numbering system; the murine Fc variant enhances the binding of the murine Fc fragment to DC cells and DC activation, including the proliferation and activation of specific T cells.

Provided is a fish in which accumulation of inosinic acid is enhanced or accelerated during ripening. In a fish of the present disclosure, the function of the ecto-5-nucleotidase (nt5e) gene is lost.